BioSpace News Archive

Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.

Incyte Corporation’s Phase III LIMBER-304 clinical trial has come to an end following a third-party investigation that forecasted poor results.

Here are some tips to help you nail virtual interviews and networking events so you can be prepared for BioSpace’s Virtual Talent Connect on March 9.

With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.

The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.

IRLAB Therapeutics AB announced that the company will present at the ABGSC Investor Day on Wednesday, March 8, 2023, in Stockholm, Sweden.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that the Company has completed all 115 implants in its DREAM U.S.

Harbour BioMed announces the positive topline results of its phase III clinical trial of batoclimab for the treatment of generalized myasthenia gravis, which is also the first positive pivotal trial outcome for batoclimab worldwide.

Sooma Medical, a medical device company based in Finland, has been granted Breakthrough Device designation by the U.S. Food and Drug Administration for its portable, patient-administered neuromodulation device to treat depression.

Positive topline results from an analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed treatment with Daiichi Sankyo and AstraZeneca’s ENHERTU® met the pre-specified target for objective response rate and demonstrated durable response across multiple HER2 expressing advanced solid tumors in heavily pre-treated patients.